XyloCor Therapeutics is a private, clinical-stage biopharmaceutical company based in King of Prussia, Pa., developing one-time gene therapies to transform outcomes for patients with cardiovascular disease. Its lead product, XC001 (encoberminogene rezmadenovec), is designed to promote new blood vessel growth in the heart to restore blood flow and reduce ischemic chest pain while minimizing systemic toxicity through local administration. Positive Phase 1/2 (EXACT-1) data published in Circulation: Cardiovascular Interventions demonstrated potential disease-modifying effects in refractory angina. XyloCor plans two randomized, double-blind Phase 2 trials in 2025: a Phase 2b EXACT-2 study using catheter-based endocardial delivery in refractory angina and a second trial evaluating XC001 as an adjunct to coronary artery bypass graft surgery (CABG). The company also has a preclinical candidate, XC002, in discovery for treating cardiac tissue damage after heart attacks. The $67.5 million Series B will fund completion of the two Phase 2 trials and support continued clinical development. XyloCor Therapeutics is developing XC001, an investigational gene therapy intended to promote angiogenesis in the heart for patients with refractory angina; XC001 is being studied in the Phase 1/2 EXACT trial. XC001 has Fast Track designation from the FDA and an open IND, and the EXACT trial—an open-label, dose-escalation study initiated in 2020—is ongoing at U.S. cardiovascular research sites. The company is also developing a second preclinical candidate, XC002, for cardiac tissue damage after heart attacks. XyloCor plans to expand XC001’s clinical program, including initiating a new trial evaluating XC001 as an adjunctive therapy to augment the effectiveness of coronary artery bypass graft surgery (CABG). Financially, the company closed an additional $22.6 million financing that builds on its 2018 Series A, bringing total investment to $41.9 million to date. XyloCor is headquartered in Malvern, Pa., was co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, and holds an exclusive license from Cornell University. XyloCor Therapeutics is a private clinical-stage biopharmaceutical company developing gene therapies to address unmet needs in cardiovascular disease. Its lead product, XC001, is an angiogenic gene therapy intended as a one-time treatment to improve exercise tolerance in patients with refractory angina, and the company also has a discovery-stage program, XC002, aimed at cardiac tissue regeneration after heart attacks. The U.S. FDA granted Fast Track designation to XC001, an IND is open, and XyloCor intends to commence clinical trials in 2019. Proceeds from the recently closed $17 million Series A will be used to advance XC001's development and to expand the company’s business and operational structure. The company is led by CEO Al Gianchetti and has expanded its board to include industry investors and academic founders, with a worldwide license to develop and commercialize XC001 from Weill Cornell Medicine. XyloCor positions XC001 as a potential option for patients with refractory angina who have no remaining standard treatment choices.

Total raised

$107M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2025